||Consumer Protection Law guidance published
||Draft guidance published and consultation
|7 February 2020
Update on CMA guidance on consumer law for IVF clinics in the UK
17 June 2020: The CMA’s work to develop consumer law guidance for the Fertility Sector in the UK is continuing. The CMA is continuing to speak to stakeholders and to undertake research.
In light of the significant impact the Coronavirus (COVID-19) pandemic has had on the Fertility Sector in the UK, the CMA has revised its timetable.
The CMA expects to publish the draft guidance for consultation in November 2020 and to publish the final guidance in March 2021. The stakeholder event scheduled for April 2020, which was cancelled due to COVID-19, will take place later in the year.
The CMA continues to want to hear from you if you have experience of any of the issues we have identified when buying IVF treatment.
Details of your experience can be shared with the CMA by email to: ConsumerLawIVFTeam@cma.gov.uk.
Before doing so, please read more on providing information to us.
9 April 2020: The CMA is aware of the severe impact that Coronavirus (COVID-19) has had on the Fertility Sector in the UK, with clinics directed by the sector regulator to stop fertility treatment by 15 April 2020, until further notice.
The CMA recognises this disruption to IVF services; but considers that its work on developing consumer law guidance for the sector remains important for the protection of consumers and will be continuing its work in this area.
However due to the current crisis the consultation on the guidance will now be released in late 2020.
7 February 2020: The Competition and Markets Authority (CMA) is undertaking work to develop guidance for IVF clinics in the UK. Currently, there is no written guidance on consumer protection law for the IVF sector.
The CMA is therefore concerned that clinics might not be aware of their obligations, and so is producing guidance which will cover issues such as:
- Price transparency: Clinics should present clear and upfront prices for their treatments.
- Potential mis-selling of treatments: Patients should not be mis-sold ‘add- on’ treatments, which are offered by some clinics and can cost up to £2,500 per cycle.
- Success rates: Clinics should not mislead patients about how successful their treatments are and should ensure that rates are accurate and up to date on their websites and in advertising.
- Unfair terms: Terms and conditions should be fair and transparent.
The CMA will be engaging with relevant stakeholders in the sector, undertaking research and working closely with the Human Fertilisation and Embryology Authority (HFEA), to understand more about whether such practices are taking place, and to develop tailored guidance for the sector.
The CMA expects to consult on the guidance in July, and to publish final guidance later in the year. The CMA will also publish advice for patients.
At this early stage, the CMA has not reached a view as to whether consumer protection law may have been broken. However, if it finds evidence that some clinics’ practices and/or terms are misleading or unfair, it could take enforcement action.
The Advertising Standards Authority (ASA) is also looking at the IVF sector and will co-ordinate its work with the CMA and HFEA. The ASA is the UK’s independent regulator of advertising. Its work includes acting on complaints and proactively checking media, to take action against misleading, harmful or offensive advertising, promotional and direct marketing. The ASA will consider all options including the use of an Enforcement Notice to put the sector on notice about the need to comply with the rules.
We want to hear from you
The CMA wants to hear from you if you have experience of any of the above issues when buying IVF treatment.
If you wish to share your relevant experience with us, please do so by 10 April 2020 at the following email: ConsumerLawIVFTeam@cma.gov.uk.
Before doing so, please be aware that the CMA will use any information you provide in performing its statutory functions, and in accordance with the restrictions on disclosure in Part 9 Enterprise Act 2002.
Initially, the information you provide will help us develop our guidance, though it may also be used to help us in considering or taking enforcement action against IVF fertility clinics, should that be appropriate.
To the extent any information you provide contains personal data under the General Data Protection Regulation 2016/679 (GDPR) or domestic legislation like the Data Protection Act 2018, there is important information you should know about how we will use your information, this is available in the document below:
Assistant Project Director
Debbie Kitcher-Jones (email@example.com)
Louise Strong (firstname.lastname@example.org)
Senior Responsible Officer
George Lusty (email@example.com)